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Multiple cases of IgA nephropathy (IgAN) may occur in
families; we compared their prognosis to sporadic cases
of this disease. We isolated macromolecular IgA1 from
60 patients with familial IgAN, 91 of their asymptomatic
relatives, 43 patients with sporadic IgAN (SpIgAN), 90 of their
asymptomatic relatives, and 43 healthy subjects. Compared
with SpIgAN patients, those with multiplex familial IgAN
(MpIgAN) had more advanced renal histopathology and
more galactose-deficient macromolecular IgA1 in their
serum. Further, when we tested the effects of the
macromolecular IgA1 on human mesangial cells in culture,
we found that the macromolecular IgA1 taken from
familial clusters had enhanced binding to mesangial cells
and caused increased expression of interleukin-6, tumor
necrosis factor-a, and monocyte chemotactic peptide-1.
The macromolecular IgA1 isolated from asymptomatic
relatives caused increased cytokine expression in the
mesangial cells when derived from MpIgAN compared
with SpIgAN or healthy controls. While these studies
suggest that macromolecular IgA1 isolated from patients
with MpIgAN is more pathogenic than that from patients
with SpIgAN, long term follow-up will be needed to clarify
the risk in asymptomatic relatives of the patients with
multiplex familial disease.
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IgA Nephropathy (IgAN), the most common primary
glomerular disease, is a major cause of end-stage renal
disease (ESRD).1 IgAN exhibits a complex trait with the
involvement of both genetic and environmental factors in the
pathogenesis. Mucosal pathogens interacting with the
mucosal IgA immune system play an important role in the
pathogenesis of IgAN.2 Deposition of polymeric IgA1
(pIgA1) and IgA1-contained immune complexes in mesan-
gium is a hallmark in IgAN. Among the abnormalities that
have been reported in IgAN, galactose-deficient (Gal-
deficient) O-linked glycans at the hinge region of the IgA1
heavy chain is the most consistent finding and has been
implicated in the pathogenesis of IgAN.3
IgA Nephropathy may occur in sporadic and familial
forms.4 Familial aggregation has been reported in Caucasian,
Latin-American, and Asian populations with the incident
rate accounting up to 10–15% of all cases in some regions.5–8
The relationship between patients in familial IgAN varies
greatly from first and second degree to more distant
relationships.8 Familial clustering suggests an inheritable
genetic predisposition of IgAN, although it does so with
incomplete penetrance, nor does it follow the Mendelian
transmission pattern.9 Recent family-based genome-wide
scan linkage studies identified several susceptibility loci,
including 6q22–23 [IGAN-1], 3p24–23, 4q26–31, 17q12–22,
and 2q36, from different cohorts, yet no single locus is
responsible for disease linkage in these studies.10 Examina-
tion of possible candidate genes, including C4 null allele,
galactosyl transferase, and major histocompatibility complex
antigens, failed to show an association with the pathogenesis
of IgAN.6
The issue that familial IgAN confers an increased risk of
progression to ESRD with a poor prognosis remains
controversial.11 Data on the nature of IgA1 molecules from
familial IgAN are limited. Recently, Gharavi et al.12 reported
the heritability of the aberrant IgA1 glycoform. Higher serum
level of Gal-deficient IgA1 is observed in multiplex familial
IgAN (MpIgAN) patients when compared with that in
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sporadic form. Moreover, elevated Gal-deficient IgA1 level is
also found among a significant portion of at-risk asympto-
matic blood-related members as compared with that among
married-in individuals, raising the notion of genetic
transmission of Gal-deficient IgA1 production. Herein, we
examined circulating macromolecular IgA1 from IgAN
patients and from relatives of patients with MpIgAN and
compared it with that isolated from patients with sporadic
IgAN (SpIgAN) and from their relatives. We further
examined whether these macromolecular IgA1 exhibited
active binding to human mesangial cells (HMCs), thus
promoting glomerular damage after mesangial deposition.
RESULTS
Clinical characteristics of IgAN patients
The clinical characteristics of the MpIgAN (also abbreviated
as FA) and SpIgAN (also abbreviated as SA) are summarized
in Table 1. The duration of follow-up for these patients varied
from 2 to 10 years. The histological grading at the time of
biopsy was higher in MpIgAN than that in SpIgAN
(P¼ 0.037). Elevation of urinary protein was detected in
MpIgAN at the time of latest follow-up as compared with
that in SpIgAN (P¼ 0.013), although the rate of changes in
urinary protein was comparable between the two groups of
IgAN patients. No significant difference was observed in
serum creatinine and glomerular filtration rate between
MpIgAN and SpIgAN.
Serum IgA1 and macromolecular IgA1 level
The serum IgA1 level of both groups of IgAN patients was
significantly higher than that in healthy controls (CL) (FA/SA
vs CL, Po0.05), despite no significant difference between
these two groups of IgAN patients (FA vs SA, NS) (Figure 1a).
The serum level of macromolecular IgA1 was higher in IgAN
patients and also in relatives of MpIgAN (FR) when
compared with that in controls (FA/SA/FR vs CL, Po0.05).
In contrast to serum IgA1, MpIgAN had a higher serum
macromolecular IgA1 level than did SpIgAN (FA vs SA,
Po0.05) (Figure 1b).
Serum level of Gal-deficient macromolecular IgA1 and their
binding to HMCs
The serum level of Gal-deficient macromolecular IgA1 (Gal-
deficient IgA1) is shown in Figure 2a. Patients with MpIgAN
had a higher serum level of Gal-deficient macromolecular IgA1
than did those with SpIgAN (FA vs SA, Po0.05). The serum
Gal-deficient macromolecular IgA1 level in both groups of
Table 1 | Clinical data of multiplex familial or sporadic IgAN
Sporadic IgAN
patients (SA)
Multiplex familial
IgAN patients (FA) P-value
Number of patients 43 60
Number of families 43 30
Gender (male/female) 13/30 20/40 NS
Gradea 1.35±0.57 1.63±0.74 0.037
Follow-up (year) 5.67±2.27 4.97±2.15 NS
Creatinine (mmol/l)
Initial 97.57±30.71 89.78±21.67 NS
Follow-up 123.43±53.05 112.00±38.41 NS
Change per year 4.73±7.82 5.82±10.27 NS
Proteinuria (g/day)
Initial 0.91±0.70 1.37±0.76 NS
Follow-up 0.97±1.04 2.25±1.37 0.013
Change per year 0.04±0.17 0.21±0.31 NS
GFR (ml/min per 1.73 mm2 body surface area)
Initial 102.64±26.77 87.07±18.50 NS
Follow-up 76.91±23.71 62.13±17.34 NS
Change per year 4.37±4.81 5.44±4.04 NS
Values are mean±s.d. Data were compared by unpaired t-test. GFR, glomerular
filtration rate; NS, not significant.
aGrade: histological grading determined by the classification published by Lai
et al.45.
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Figure 1 | Serum IgA1 and macromolecular IgA1 level. Serum
level of (a) total IgA1 and (b) macromolecular IgA1 in healthy
subjects (CL, ’), asymptomatic relatives of SpIgAN (SR, m),
SpIgAN (SA, .), asymptomatic relatives of MpIgAN (FR, ~), and
MpIgAN (FA, K). Horizontal line indicates the median value of
each group. The table below each graph depicts statistical
analysis between groups using the Kruskal–Wallis test. NS
indicates statistically not significant with P40.05.
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Figure 2 | Serum level of Gal-deficient macromolecular IgA1
and their binding to HMCs. (a) Serum level of galactose-deficient
macromolecular IgA1 and (b) binding of human mesangial cell to
macromolecular IgA1 purified from healthy subjects (CL, ’),
asymptomatic relatives of SpIgAN (SR, m), SpIgAN (SA, .),
asymptomatic relatives of MpIgAN (FR, ~) and MpIgAN (FA, K).
Horizontal line indicates the median value of each group.
Gal-deficient macromolecular IgA1 was measured by HAA
lectin-binding assay expressed as OD 405 nm. Binding of HMCs
to macromolecular IgA1 was determined by flow cytometry
expressed as mean fluorescent intensity (MFI). The table below
each graph depicts statistical analysis between groups by the
Kruskal–Wallis test. NS indicates statistically not significant with
P40.05.
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IgAN patients was also significantly higher than that in their
corresponding family relatives or in the healthy controls (FA vs
FR and SA vs relatives of SpIgAN (SR), Po0.001; and FA/SA vs
CL, Po0.001). Most intriguingly, asymptomatic relatives of
patients with MpIgAN showed a higher serum Gal-deficient
macromolecular IgA1 level than did the controls or relatives of
those with SpIgAN (FR vs CL/SR, Po0.001), with no
difference in the serum Gal-deficient macromolecular IgA1
level between controls and relatives of SpIgAN (CL vs SR, NS).
A similar finding was observed for HMCs binding of
macromolecular IgA1 (Figure 2b). There was higher HMCs
binding of macromolecular IgA1 from MpIgAN (FA vs SA,
Po0.05). The HMCs binding of macromolecular IgA1 for both
groups of IgAN patient was significantly higher than their that
in corresponding family relatives or controls (FA vs FR and SA
vs SR, Po0.001; FA/SA vs CL, Po0.001). Relatives of MpIgAN
patients exhibited higher macromolecular IgA1 binding to
HMCs when compared with controls or relatives of SpIgAN
patients (FR vs CL/SR, Po0.01).
Cytokines production by HMCs cultured with macromolecular
IgA1
Figure 3 depicts the gene expression and protein synthesis of
interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), and
monocyte chemotactic peptide-1 (MCP-1) in HMCs cultured
with macromolecular IgA1. Compared with SpIgAN, macro-
molecular IgA1 from MpIgAN induced a higher cytokine
production by cultured HMCs (FA vs SA, Po0.05).
Macromolecular IgA1 from MpIgAN induced twofold
increases in the mRNA expression of MCP-1 and TNF-a by
HMCs. Protein synthesis of MCP-1 and TNF-a was increased
by two- and 25-fold, respectively, under similar experimental
conditions. More strikingly, macromolecular IgA1 from
MpIgAN induced 18- and 390-fold increases in the mRNA
expression (FA, median¼ 1965, range: 832–5257; SA, med-
ian¼ 106, range: 18–1060) and protein synthesis of IL-6,
respectively (FA, median¼ 1426, range: 420–2798; SA,
median¼ 3.66, range: 2–11.64) as compared with that from
SpIgAN. Macromolecular IgA1 from relatives of the MpIgAN
family also induced greater synthesis of IL-6 and MCP-1
when compared with that from controls or relatives of the
SpIgAN family (FR vs CL/SR, Po0.01). Similarly, the
expression of these cytokines by HMCs cultured with
macromolecular IgA1 from controls did not differ from that
of relatives of SpIgAN (SR vs CL, NS). The increased
expression of IL-6, TNF-a, and MCP-1 by HMCs cultured
with macromolecular IgA1 was abolished after the fractions
were depleted of IgA1 (Supplementary Table 1), excluding
the potential presence of other biologically active compo-
nents in the macromolecular IgA1 fractions.
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Figure 3 | Expression of cytokines in HMC cultured with macromolecular IgA1. Gene expression and protein release of IL-6, MCP-1, and
TNF-a in HMCs cultured with macromolecular IgA1 purified from healthy subjects (CL, ’), asymptomatic relatives of SpIgAN (SR, m),
SpIgAN (SA, .), asymptomatic relatives of MpIgAN (FR, ~), and MpIgAN (FA, K). Horizontal line indicates the median value of each
group. HMCs were cultured with 750 ng/ml macromolecular IgA1 and gene expression and protein release were examined after 4 or 48 h
incubation. The gene expression is expressed as fold change related to the value of medium control (HMCs cultured in plain medium
without macromolecular IgA1). The table below each graph depicts statistical analysis between groups using the Kruskal–Wallis test.
NS indicates statistically not significant with P40.05.
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Data of cytokine production by HMCs were further
confirmed by time- and dose–response studies. Patients with
MpIgAN induced greater production of IL-6, TNF-a, and
MCP-1 by HMCs for all time points examined as compared
with those with SpIgAN (FA vs SA, Po0.05) (Figure 4).
Macromolecular IgA1 from MpIgAN induced a sustained
gene expression of IL-6 and MCP-1 by cultured HMCs,
which peaked at 24 and 8 h, respectively, as compared with
4 h for macromolecular IgA1 from SpIgAN. The cytokine
production by HMCs increased with the concentration of
incubating macromolecular IgA1 in a dose-dependent
manner, more so with macromolecular IgA1 from MpIgAN
(Figure 5). A low concentration of macromolecular IgA1
from MpIgAN (28 ng/ml) achieved an increased gene
expression of cytokine in HMCs than did a higher
concentration of macromolecular IgA1 from SpIgAN
(83.5 ng/ml). Consistent with the mRNA results, significant
increases in protein expression of MCP-1 and TNF-a were
readily detected in HMCs incubated with macromolecular
IgA1 from MpIgAN at a concentration of 28 ng/ml. However,
a higher concentration of macromolecular IgA1 from
SpIgAN (4250 ng/ml) was required to induce a comparable
level of protein synthesis of MCP-1 and TNF-a.
Correlation analysis
The correlations between serum level of Gal-deficient
IgA1, HMCs binding of macromolecular IgA1, and the
cytokine production by HMCs after binding to macro-
molecular IgA1 were examined. There was no correlation
between HMCs binding of macromolecular IgA1 and
serum level of Gal-deficient macromolecular IgA1, or the
cytokine production by HMCs (Tables 2 and 3). In
contrast, the gene expression of IL-6 and MCP-1 in HMCs
cultured with macromolecular IgA1 correlated with the
serum level of Gal-deficient macromolecular IgA1 in
patients with IgAN and in their relatives (Po0.05), but
not in healthy controls (Table 2). The synthesis of IL-6
and MCP-1 by HMCs cultured with macromolecular
IgA1 correlated well in all studied subjects (Po0.05)
(Table 4).
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Figure 4 | Gene expression and protein release of IL-6, MCP-1, and TNF-a in HMCs cultured with 750 ng/ml macromolecular IgA1 for
different time points. Results were obtained from experiments using three independent samples (each sample was pooled from 10
randomly selected cases in each group) and are expressed as mean±s.e.m. The gene expression is expressed as fold change related to the
value of medium control. Data were analyzed by one-way analysis of variance with Bonferroni’s correction. *Po0.05, #Po0.01, dPo0.001
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Table 2 | Correlation between serum level of Gal-deficient macromolecular IgA1and the HMCs binding of macromolecular IgA1
or macromolecular IgA1-induced cytokine production by HMCs
IL-6 MCP-1 TNF-a
HMCs binding mRNA Protein mRNA Protein mRNA Protein
CL r=0.1345 r=0.2983 r=0.0034 r=0.0643 r=0.1167 r=0.0083 r=0.0715
NS NS NS NS NS NS NS
SR r=0.3124 r=0.2179 r=0.3157 r=0.3124 r=0.0461 r=0.1012 r=0.0332
NS P=0.0479 P=0.0037 P=0.0040 NS NS NS
SA r=0.1439 r=0.3181 r=0.3482 r=0.4242 r=0.0368 r=0.2497 r=0.2625
NS P=0.0427 P=0.0471 P=0.0057 NS NS NS
FR r=0.0450 r=0.2390 r=0.4974 r=0.3807 r=0.1943 r=0.0778 r=0.1307
NS P=0.0296 Po0.0001 P=0.0002 NS NS NS
FA r=0.1980 r=0.3398 r=0.7601 r=0.4512 r=0.1150 r=0.6726 r=0.0188
NS P=0.0128 Po0.0001 P=0.0006 NS Po0.0001 NS
HMCs, human mesangial cells; IL, interleukin; MCP, monocyte chemotactic peptide; NS, not significant; r, spearman’s correlation r; TNF, tumor necrosis factor.
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DISCUSSION
In this study, we present our novel finding that there is an
enhanced reactivity of HMCs toward macromolecular IgA1
isolated from MpIgAN as compared with that toward
macromolecular IgA1 from SpIgAN. Such enhanced reactiv-
ity may be relevant to the disease progression in MpIgAN.
Interestingly, this increased HMCs reactivity was also
evidenced, although to a lesser extent, in asymptomatic
family relatives of MpIgAN. Familial IgAN was initially
reported in the late 1970s,13,14 with an increasing recognition
in the past two decades mainly in European population.8,15
IgAN is the most common primary glomerular disease in
China,16 but data of familial IgAN in the Chinese population
are limited.17,18 MpIgAN is reportedly associated with a
poorer renal prognosis, with 64% developing into ESRD
whereas only 8% does so in SpIgAN.11 However, a recent
study suggests that the presence of familial disease does not
confer an increased risk for disease progression.19 In this
study, we have adopted a functional approach by comparing
the HMCs reactivity toward Gal-deficient macromolecular
IgA1 from multiplex familial or SpIgAN, thereby providing
additional pathogenetic data to address these controversial
findings.
Neither clinical data nor the renal histological staining
pattern is useful in differentiating multiplex familial from
SpIgAN.19,20 Our current data also show that there was no
difference in serum creatinine or glomerular filtration rate
between MpIgAN and SpIgAN, either at the time of first
presentation or latest follow-up, for an intermediate period
averaging 5 years. However for proteinuria, a proven
prognostic marker in IgAN, a significant difference was
observed between two groups of patients at the latest follow-
up, although just failing to reach a statistical difference when
the data were normalized with the duration of follow-up.
This may not be surprising with the variable progression rate
for IgAN patients reaching ESRD within a few years to more
than 50 years.21 Contrary to the Italian data,19 we observed a
severer histological grading in MpIgAN patients at first
biopsy. It may suggest that familial aggregation is associated
with a more advanced renal lesion. As the serum creatinine,
proteinuria, and glomerular filtration rate were comparable
between MpIgAN and SpIgAN at the time of first biopsy, the
histological findings were less likely to be because of sampling
bias. With the variable, relentless, and slowly progressive
course of IgAN, our study acknowledged the drawback of
including patients with different follow-up durations or
treatment protocols. Instead, we examined the possible
inherent role of Gal-deficient macromolecular IgA1 on
HMCs binding and reactivity. These macromolecular IgA1s
were isolated from MpIgAN and SpIgAN during clinical
quiescence. Our study of the intrinsic reactivity of
macromolecular IgA1 to HMCs should unlikely be influ-
enced by the rate of progression and treatment protocols of
the disease.
Table 3 | Correlation between the HMCs binding of macromolecular IgA1 and macromolecular IgA1-induced cytokine
production by HMCs
IL-6 MCP-1 TNF-a
mRNA Protein mRNA Protein mRNA Protein
CL r=0.2058 r=0.2885 r=0.2930 r=0.2604 r=0.1540 r=0.2570
NS NS NS NS NS NS
SR r=0.0629 r=0.2177 r=0.0766 r=0.0887 r=0.1307 r=0.1005
NS NS NS NS NS NS
SA r=0.1017 r=0.1361 r=0.0746 r=0.0269 r=0.2093 r=0.0250
NS NS NS NS NS NS
FR r=0.0017 r=0.1443 r=0.0769 r=0.1044 r=0.0844 r=0.2461
NS NS NS NS NS NS
FA r=0.1777 r=0.2434 r=0.0451 r=0.0786 r=0.1024 r=0.1761
NS NS NS NS NS NS
HMCs, human mesangial cells; IL, interleukin; MCP, monocyte chemotactic peptide; NS, not significant; r, spearman’s correlation r; TNF, tumor necrosis factor.
Table 4 | Correlation between different cytokines production
by HMCs following incubation with macromolecular IgA1
IL-6 vs MCP-1 IL-6 vs TNF-a MCP-1 vs TNF-a
mRNA Protein mRNA Protein mRNA Protein
CL r=0.9686 r=0.4843 r=0.8980 r=0.0824 r=0.9408 r=0.1836
Po0.0001 P=0.0012 Po0.0001 NS Po0.0001 NS
SR r=0.8812 r=0.2955 r=0.5160 r=0.0307 r=0.5112 r=0.1384
Po0.0001 P=0.0052 Po0.0001 NS Po0.0001 NS
SA r=0.5125 r=0.5184 r=0.4988 r=0.0626 r=0.3953 r=0.2964
P=0.0004 P=0.0010 P=0.0007 NS P=0.0087 NS
FR r=0.6566 r=0.4614 r=0.4757 r=0.2123 r=0.5946 r=0.1698
Po0.0001 Po0.0001 Po0.0001 NS Po0.0001 NS
FA r=0.4424 r=0.2772 r=0.4584 r=0.1785 r=0.5362 r=0.0042
P=0.0006 P=0.0386 P=0.0003 NS Po0.0001 NS
HMCs, human mesangial cells; IL, interleukin; MCP, monocyte chemotactic peptide;
NS, not significant; r, spearman’s correlation r; TNF, tumor necrosis factor.
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Gharavi et al.12 reported the presence of elevated
circulating Gal-deficient IgA in MpIgAN. The current
consensus supports a key role of Gal-deficient pIgA1 in the
pathogenesis of IgAN, as Gal-deficient pIgA1 can self-
aggregate or bind to soluble IgA Fc receptor or other
circulating proteins, including C3, IgG, IgM, and fibronectin,
to form circulating IgA1-immune complexes with an
aberrant glycosylation pattern22 that may favor mesangial
deposition of these complexes.3,22–24 However, the exact
mechanism leading to mesangial deposition of pIgA1 is not
yet satisfactorily defined. Novak et al.25 observed that HMCs
bound better to the Gal-deficient pIgA1 myeloma protein
than to the normal galactosylated IgA1 myeloma protein.
Moreover, immune complexes containing Gal-deficient
pIgA1 isolated from IgAN patients bound better to HMCs
than did the Gal-deficient pIgA1 myeloma protein. This
suggests that aberrant glycosylation of macromolecular
IgA1 is not the only determinant controlling mesangial
binding; and other factors are also involved. We had shown
earlier that mesangial binding of macromolecular IgA1 could
be size- and charge-dependent.26,27 Our present results show
no significant correlations between the amounts of Gal-
deficient macromolecular IgA1 with their HMCs binding or
with their induction of protein expression of TNF-a and
MCP-1 by HMCs. Our data implicate that both the quantity
and quality of macromolecular IgA1 from SpIgAN and
MpIgAN may influence the binding of macromolecular IgA1
and their activation of HMCs. Heterogeneity of the size of
macromolecular IgA1 has been shown earlier28 and induction
of HMCs proliferation has been restricted to the macro-
molecular IgA1 of size 800–900 kDa.29 Other than the size,
the number and sites of attachment of the Gal-deficient O-
linked glycans of macromolecular IgA1 may also have an
effect on their activity on HMCs. It has been suggested that
not all the terminal Gal-deficient GalNAc residues of IgA1-
immune complexes are occupied by anti-GalNAc antibo-
dies.22 The HAA reactivity with the exposed GalNAc can be
affected by the sites of attachment by anti-GalNAc antibodies,
which in turn may alter the conformation and size of the
IgA1-immune complexes and affect the HMCs binding
characteristics.22 Moreover, deletion of either O- or N-linked
glycans affects the binding of macromolecular IgA1 to a
transferrin receptor suggesting the possible involvement of
N-linked glycans in mesangial reactivity toward macromo-
lecular IgA1.30 Not surprisingly, the lack of correlation
between circulating Gal-deficient macromolecular IgA1 and
our present laboratory data may be explained by the
intermingled factors in controlling the HMCs binding and
reactivity of the ‘pathological macromolecular IgA1.’
Whether there are qualitative differences in the size, anti-
glycan antibodies occupancy, and conformation and se-
quence of the polypeptide chain of the macromolecular IgA1
between SpIgAN and MpIgAN deserves further detailed
investigation.
In this study, we documented elevated serum levels of total
macromolecular IgA1 and Gal-deficient macromolecular
IgA1 with enhanced binding to HMCs in MpIgAN when
compared with that in SpIgAN. Moreover, these findings
were demonstrable in relatives of MpIgAN but not in
relatives of SpIgAN or in healthy controls. These findings
implicate a potential for disease development in asympto-
matic relatives of MpIgAN if aberrant glycosylation con-
tributes an inherited risk factor for the pathogenesis of IgAN
as illustrated in the recurrence of IgAN in renal allograft.
Additional genetic and environmental factors may be
involved for full manifestation of the disease. Alternatively,
it is plausible to speculate that IgAN is developed only when
the level of Gal-deficient macromolecular IgA1 has reached a
threshold high enough to trigger subsequent pathological
events in the glomerular mesangium. Future research is
obviously warranted for long-term follow-up to clarify the
potential risk of developing IgAN in asymptomatic relatives
of MpIgAN so that early diagnosis and better management
can be facilitated.
Stimulation of HMCs with high molecular IgA leads to
enhanced production of proinflammatory cytokines, IL-6
and TNF-a, and chemokine, MCP-1.31–33 TNF-a can induce
renal damage in glomerulonephritis,34 and mesangial-derived
TNF-a is an important mediator in the glomerulo-tubular
communication, which leads to further tubulointerstitial
damage in IgAN.35 Moreover, mesangial-derived TNF-a
downregulates podocyte markers, resulting in altered
glomerular permeability and enhanced proteinuria in
IgAN.36 Polymorphism of the TNF gene, an infrequent allele
2 at position -308, has also been shown to associate
with gross hematuria in IgAN.37 IL-6 induces glomerular
inflammation through mesangial proliferation and extra-
cellular-matrix macromolecules production.38 Increased in-
tra-renal expression of IL-6 correlates with disease severity in
IgAN.39 Renal damage can be further amplified by IL-6 and
MCP-1 by activation and recruitment of lymphocytes,
neutrophils, and monocytes.40 MCP-1 can be induced by
IL-6 in peripheral blood mononuclear cells41 and in HMCs.42
MCP-1 regulates leukocyte trafficking by promoting
the directional migration of mononuclear phagocytes.43
The soluble form of IL-6 receptor (sIL-6R) induces
cultured HMCs to release MCP-1 in combination with
IL-6 at concentrations comparable with the range as
measured in biological fluids,42 although in vivo data are
not available. Nevertheless, the presence of both IL-6 and
sIL-6R in renal biopsy from patients with IgAN is indicative
of severe histological damages and disease exacerbation.44
In this study, we observed that a higher expression of IL-6,
MCP-1, and TNF-a was detected in HMCs incubated
only with macromolecular IgA1 from MpIgAN. Taken
together, our in vitro data suggest that patients from a
multiplex IgAN family are more likely to have severer
mesangial injuries and tubulointerstitial damage, with a
higher risk to develop ESRD. Prolonged follow-up period and
repeated biopsy from MpIgAN and SpIgAN, if feasible, will
provide a more definitive answer to the prognostic course for
MpIgAN.
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MATERIALS AND METHODS
Study population
The study protocol was approved by the Research Ethics Committee
of the Queen Mary Hospital, Hong Kong and was carried out in
accordance with the principles of the Declaration of Helsinki. All
patients, relatives, and healthy controls gave their written informed
consent. MpIgAN refers to patients with two family members having
biopsy-proven IgAN. SpIgAN refers to patients in whom the disease
occurs only in the patient and all remaining family members have
normal urinalysis. Control subjects are defined as healthy volunteers
without urinary abnormalities and a negative familial history of
kidney disease. Subjects recruited in the study included (i) 60 IgAN
index patients from 30 multiplex IgAN families; (ii) 91 asympto-
matic first-degree blood-related relatives from a multiplex IgAN
family with married-in relatives excluded; (iii) 43 SpIgAN patients;
(iv) 90 first-degree relatives of SpIgAN patients; and (v) 43 healthy
subjects. All subjects are Southern Chinese with Han ethnicity. Fifty
milliliters of blood were collected from each studied subject at
clinical quiescence (no macroscopic hematuria with urinary
erythrocyte count o10,000/ml in un-centrifuged urine). The serum
was isolated and frozen at 201C until isolation of macromolecular
IgA1. Serum IgA1 levels were determined by nephelometry. In
addition, the clinical characteristics of IgAN patients were evaluated
according to our earlier publication.45
Purification of macromolecular IgA1
Jacalin-binding protein was purified using a jacalin-agarose affinity
column and macromolecular IgA1 was fractionated by fast protein
liquid chromatography (Pharmacia, Uppsala, Sweden) as described
earlier.46.The identity of macromolecular IgA1 after fast protein
liquid chromatography was confirmed by anti-IgA affinity chroma-
tography and an IgA sandwich enzyme-linked immunosorbent assay
(ELISA). Macromolecular IgA1 was the high-molecular-mass IgA1
or IgA1-immune complexes with molecular weights between 250
and 1000 kDa containing a secretory component and C3. The purity
of macromolecular IgA1 fractions was confirmed by SDS-poly-
acrylamide gel electrophoresis and by ELISA.32
Culture of HMCs
Isolation and characterization of HMCs were performed as
described earlier.47 Glomeruli were isolated from human cadaveric
kidney confirmed histologically to show no renal pathology.
Glomerular cells were grown in an RPMI 1640 medium supple-
mented with glutamine (2 mmol/l), N-[2-hydroxyethyl]-piperazine-
N0-[2-ethanesulfonic acid] (HEPES; 10 nmol/l), penicillin (50 U/
ml), streptomycin (50 mg/ml), and 12% fetal calf serum, incubated
in an atmosphere of 5% CO2/95% air. Mesangial cells were used at
the seventh to tenth passages.
Enzyme-linked lectin-binding assays
For enzyme-linked lectin-binding assays, 96-well microtiter plates
(Immunlon 2, Dynatech, Marnes la Coquette, France) were coated
overnight at 41C with a F(ab0)2 fragment of goat anti-human IgA
(BioSource International, Camarillo, CA, USA) at a concentration of
10 mg/ml diluted in a carbonate-bicarbonate buffer, pH 9.6. The
plates were blocked with 1% bovine serum albumin (Sigma, St
Louis, MO, USA) in a phosphate-buffered saline containing 0.05%
Tween-20 (v/v) for 1 h at 371C. The samples diluted in the blocking
buffer were added to each well and incubated overnight at 41C.
To avoid any increased binding of IgA because of elevated
IgA concentrations in samples from patients, all samples were
appropriately diluted to achieve comparable levels of macromole-
cular IgA1 (50mg/ml). The captured macromolecular IgA1 was
subsequently de-sialylated by treatment for 3 h at 371C with 10 mU/
ml neuraminidase from Vibrio cholerae (Roche, Indianapolis, IN,
USA) in a 100 mM sodium acetate buffer, pH 5.23 Samples were then
incubated for 2 h at 371C with biotinylated lectins from Helix
aspersa (HAA) (Sigma) diluted 1:500 in the blocking buffer.23
Bound lectins were measured by the addition of Streptavidin-
alkaline phosphatase (Dako, Glostrup, Denmark) diluted 1:6000 and
incubated for 1 h at 371C. After washing, 100 ml per well nitroblue
tetrazolium chloride (Sigma) was added and was incubated for a
minimum of 30 min in the dark at room temperature. Finally, the
reaction was terminated by the addition of 50 ml per well NaOH
(2M) and absorbance was measured at 405 nm. Results were
expressed as optical density units (OD unit).
Determination of mesangial binding of macromolecular IgA1
Human mesangial cells were grown to log phase and harvested by
incubation with 0.05%. Trypsin/0.02% ethylene-diamintetraacetic
acid in phosphate-buffered saline for 5 min at room temperature.
The cells were then adjusted to 1 107/ml and 100 ml of a cell
suspension was used in binding assays. All stainings were performed
at 41C with a staining buffer (phosphate-buffered saline with 1%
fetal bovine serum and 0.1% sodium azide). The cells were
incubated with 50 mg/ml macromolecular IgA1 for 30 min. After
incubation, the cells were washed with the staining buffer and then
further incubated with 100ml of a fluorescein isothiocyanate
(FITC)-conjugated F(ab0)2 fragment of rabbit anti-human IgA
(Dako). Background control staining was achieved by reaction with
a pre-immune F(ab0)2 fragment of a fluorescein-labeled isotypic
antibody. The stained cells were analyzed using a flowcytometer
(Coulter Electronic, Miami, FL, USA). A minimum of 10,000 cells
for each sample were analyzed. Binding of macromolecular IgA1 to
cells was expressed as mean fluorescence intensity.
Effect of macromolecular IgA1 on IL-6, MCP-1, and TNF-a
expression in HMCs
Growth-arrested HMCs were cultured in a six-well plate (1 106
cells per well) with medium containing 0.5%. Fetal bovine serum
and incubated with macromolecular IgA1 (final concentration of
750 ng/ml) for either 4 h (for reverse transcriptase-PCR) or 48 h (for
ELISA). After culture, the cells were collected for total RNA isolation
and the supernatants were stored at 701C before being analyzed
with ELISA. To study the effect of incubation time or doses of
macromolecular IgA1 on cytokine expression by HMCs, HMCs were
cultured either with increasing concentration (0–2250 ng/ml) of
macromolecular IgA1 for 4 h (for RT-PCR) or 48 h (for ELISA) or
with 750 ng/ml of macromolecular IgA1 for various time points
(0–120 h).
Real-time reverse transcriptase-PCR
Total RNA was extracted using a NucleoSpin RNA II kit
(Macherey-Nagel, Duren, Germany). Five micrograms of total
RNA were reverse transcribed to cDNA with M-MLV reverse
transcriptase (Promega, Madison, WI, USA). Real-time PCR
amplification was performed in an ABI Prism 7500 sequence
detection system using the SYBR-Green kit (Applied Biosystems,
Foster City, CA, USA). Primer sequences and GenBank accession
numbers are listed in Table 5. Data obtained were analyzed using the
comparative CT (cycle threshold) method.
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ELISA of IL-6, MCP-1, and TNF-a in culture supernatants
Interleukin-6 and TNF-a were determined with the ELISA kits from
PeproTech Inc., (Rocky Hill, NJ, USA) and MCP-1 was determined
with an ELISA kit from Bender MedSystems, (San Brunc, CA, USA).
The detection sensitivity was 32 pg/ml for IL-6 and TNF-a, and
74 pg/ml for MCP-1. The inter-batch coefficients of variation for
IL-6, TNF-a, and MCP-1 were 6.7, 7.9, and 5.8%, respectively.
Statistics
Data were expressed in either median with range or means±s.e.m.
Analysis was performed by GraphPad Prism v4.0 software using the
Kruskal–Wallis test followed by Dunn’s multiple comparison or the
unpaired t-test. All P-values quoted are two-tailed and the
significance is defined as Po0.05.
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